Research programme: restenosis therapies - NitroMed

Drug Profile

Research programme: restenosis therapies - NitroMed

Latest Information Update: 22 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boston Scientific Corporation; NitroMed
  • Developer NitroMed
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 31 Dec 2005 NitroMed and Boston Scientific have completed their collaboration on nitric oxide coated stents
  • 31 Dec 2003 Nitromed and Boston Scientific have extended an agreement to co-promote and co-develop nitric oxide coated stents worldwide
  • 30 Nov 2001 Preclinical trials in Coronary artery restenosis in USA (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top